al Translational Research Enterprise), the first UK national Kidney biobank led by Kidney Research UK. NURTuRE contains multimodal imaging datasets including digital pathology, whole slide multiplex immunofluorescence, spatial transcriptomics, and clinical data from 1000 patients. You will collaborate with experienced AZ interdisciplinary scientists with diverse backgrounds and an exceptional academic mentor specifically aligned to the project, to develop computational pathology approaches to uncover new patient stratification biomarkers from spatial data and relate these biomarkers to disease outcomes, using them to identify new therapeutic targets.
Supported by Arthur Lewis (Director) and Magnus Soderburg (Senior Director, Pathologist) at AstraZeneca, you'll also receive academic mentorship and guidance from Fabian Spill, Professor of Applied Mathematics at the University of Birmingham. You will work in an industry-leading group with a strong publication track record and be supported by a leading academic supervisor.
Accountabilities
Our Postdoctoral Fellow will conduct ground-breaking research using computational pathology, computer vision, and machine learning methods for the identification of spatial imaging biomarkers of patient risk stratification. You will develop computational tools to integrate features from multimodal datasets including digital pathology, whole slide multiplex immunofluorescence, spatial transcriptomics, and clinical data. This will involve the application of innovative machine learning techniques including foundation models, transfer learning, and GenAI to characterize the disease, uncover potential new imaging biomarkers of disease progression, and identify novel tissue biomarker patterns that can identify patient phenotypes that allow for much-needed improved patient stratification in clinical trials in renal disease.
- Research, design, and implement innovative computational pathology tools to characterize disease, uncover potential new biomarkers of disease progression, and identify novel tissue biomarkers that can identify patient phenotypes to improve patient stratification in clinical trials in renal disease.
